| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $73,069 | 15 | 100 |
Sells | $0 | 0 | 0 |
| SKIBSTED RUSSELL | Chief Financial Officer | 2 | $11,784 | 0 | $0 | $11,784 |
| Ng George K | Chief Executive Officer | 2 | $10,888 | 0 | $0 | $10,888 |
| Bigora Sian | Chief Development Officer | 2 | $10,684 | 0 | $0 | $10,684 |
| Guy Wendy | Chief Administrative Officer | 2 | $9,401 | 0 | $0 | $9,401 |
| Young David | Pres. Research & Development | 2 | $9,177 | 0 | $0 | $9,177 |
| Lin Patrick | Chief Business - Strategy Off | 2 | $8,130 | 0 | $0 | $8,130 |
| Baluch Khoso | director | 1 | $5,752 | 0 | $0 | $5,752 |
| Pannu Geraldine | director | 1 | $5,253 | 0 | $0 | $5,253 |
| Neal James R | director | 1 | $2,000 | 0 | $0 | $2,000 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Over the last 12 months, insiders at Processa Pharmaceuticals, Inc. have bought $73,069 and sold $0 worth of Processa Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Processa Pharmaceuticals, Inc. have bought $138,424 and sold $52,501 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SKIBSTED RUSSELL (Chief Financial Officer) — $11,784. Ng George K (Chief Executive Officer) — $10,888. Bigora Sian (Chief Development Officer) — $10,684.
The last purchase of 1,545 shares for transaction amount of $4,589 was made by Young David (Pres. Research & Development) on 2026‑04‑15.
| 2026-04-15 | Young David | Pres. Research & Development | 1,545 0.0684% | $2.97 | $4,589 | +5.88% | ||
| 2026-04-15 | Bigora Sian | Chief Development Officer | 1,799 0.0797% | $2.97 | $5,343 | +5.88% | ||
| 2026-04-15 | Ng George K | Chief Executive Officer | 1,843 0.0816% | $2.97 | $5,474 | +5.88% | ||
| 2026-04-15 | Lin Patrick | Chief Business - Strategy Off | 1,369 0.0606% | $2.97 | $4,066 | +5.88% | ||
| 2026-04-15 | Guy Wendy | Chief Administrative Officer | 1,583 0.0701% | $2.97 | $4,702 | +5.88% | ||
| 2026-04-15 | SKIBSTED RUSSELL | Chief Financial Officer | 1,984 0.0879% | $2.97 | $5,892 | +5.88% | ||
| 2026-03-31 | Young David | Pres. Research & Development | 1,810 0.0802% | $2.54 | $4,588 | +10.81% | ||
| 2026-03-31 | Bigora Sian | Chief Development Officer | 2,107 0.0934% | $2.54 | $5,341 | +10.81% | ||
| 2026-03-31 | Ng George K | Chief Executive Officer | 2,136 0.0946% | $2.54 | $5,415 | +10.81% | ||
| 2026-03-31 | Lin Patrick | Chief Business - Strategy Off | 1,603 0.071% | $2.54 | $4,064 | +10.81% | ||
| 2026-03-31 | Guy Wendy | Chief Administrative Officer | 1,854 0.0822% | $2.54 | $4,700 | +10.81% | ||
| 2026-03-31 | Baluch Khoso | director | 2,269 0.1005% | $2.54 | $5,752 | +10.81% | ||
| 2026-03-31 | SKIBSTED RUSSELL | Chief Financial Officer | 2,324 0.103% | $2.54 | $5,891 | +10.81% | ||
| 2026-03-31 | Pannu Geraldine | director | 2,072 0.0918% | $2.54 | $5,253 | +10.81% | ||
| 2026-03-31 | Neal James R | director | 789 0.035% | $2.54 | $2,000 | +10.81% | ||
| 2025-01-27 | Young David | Pres. Research & Development | 124,500 4.3802% | $0.80 | $99,289 | -58.60% | ||
| 2025-01-27 | Ng George K | Chief Executive Officer | 87,200 3.0679% | $0.80 | $69,542 | -58.60% | ||
| 2025-01-27 | Lin Patrick | Chief Business - Strategy Off | 43,500 1.5304% | $0.80 | $34,691 | -58.60% | ||
| 2025-01-27 | Yorke Justin W | director | 12,400 0.4363% | $0.80 | $9,889 | -58.60% | ||
| 2024-02-07 | Young David | Pres. Research & Development | 21,000 0.9297% | $2.45 | $51,526 | -31.39% |
| Young David | Pres. Research & Development | 12107 0.5343% | $37,531.70 | 11 | 0 | <0.0001% |
| Bigora Sian | Chief Development Officer | 5510 0.2432% | $17,081.00 | 2 | 0 | |
| Ng George K | Chief Executive Officer | 5492 0.2424% | $17,025.20 | 4 | 0 | <0.0001% |
| Lin Patrick | Chief Business - Strategy Off | 4725 0.2085% | $14,647.50 | 12 | 0 | <0.0001% |
| Guy Wendy | Chief Administrative Officer | 4693 0.2071% | $14,548.30 | 2 | 0 | |
| SKIBSTED RUSSELL | Chief Financial Officer | 4308 0.1901% | $13,354.80 | 2 | 0 | |
| Baluch Khoso | director | 2325 0.1026% | $7,207.50 | 1 | 0 | |
| Pannu Geraldine | director | 2188 0.0966% | $6,782.80 | 1 | 0 | |
| Neal James R | director | 818 0.0361% | $2,535.80 | 1 | 0 | |
| BESSER JAMES E | 648300 28.6128% | $2.01M | 1 | 6 | ||
| Stanker James H | Chief Financial Officer | 36510 1.6114% | $113,181.00 | 2 | 0 | |
| Floyd Robert Michael | Chief Operating Officer | 28000 1.2358% | $86,800.00 | 1 | 0 | |
| Yorke Justin W | director | 12400 0.5473% | $38,440.00 | 2 | 5 | <0.0001% |
$29,645,465 | 28 | 8.09% | $6.49M | |
$63,749,694 | 24 | -12.24% | $6.94M | |
$1,043,811 | 23 | -13.30% | $6.84M | |
$37,200,153 | 21 | -47.67% | $9.09M | |
$6,733,543 | 17 | -19.02% | $9.49M | |
$79,536,861 | 15 | -6.81% | $5.4M | |
$25,487,383 | 15 | -4.37% | $7.94M | |
$742,412 | 14 | -50.36% | $5.53M | |
$188,726 | 11 | -28.87% | $7.82M | |
$105,917 | 11 | -28.06% | $9.43M | |
Processa Pharmaceuticals, Inc. (PCSA) | $405,510 | 11 | -46.23% | $7.02M |
$241,042 | 9 | -11.02% | $9.32M | |
$159,974 | 7 | -18.60% | $9.18M | |
$5,117,729 | 6 | -52.29% | $8.7M | |
$149,778 | 4 | -45.16% | $6.04M | |
$28,395 | 3 | 3.48% | $6.67M | |
$1,057,000 | 3 | 5.27% | $5.83M | |
$31,190 | 2 | -14.17% | $7.43M | |
$4,423 | 2 | 3.27% | $6.37M |
| Increased Positions | 7 | +36.84% | 79,067 | +108.44% |
| Decreased Positions | 9 | -47.37% | 36,803 | -50.48% |
| New Positions | 3 | New | 62,521 | New |
| Sold Out Positions | 7 | Sold Out | 7,917 | Sold Out |
| Total Postitions | 17 | -10.53% | 115,174 | +57.97% |
| Stonepine Capital Management, Llc | $121.00 | 2.06% | 41,208 | +41,208 | New | 2025-09-30 |
| Geode Capital Management, Llc | $36.00 | 0.61% | 12,132 | +10,109 | +499.7% | 2025-09-30 |
| Vanguard Group Inc | $34.00 | 0.58% | 11,528 | +10,551 | +1,079.94% | 2025-09-30 |
| Virtu Financial Llc | $5.00 | 0.08% | 1,634 | -2,555 | -60.99% | 2025-09-30 |
| Two Sigma Securities, Llc | $4.00 | 0.07% | 1,450 | +1,450 | New | 2025-09-30 |
| Citigroup Inc | $4.00 | 0.07% | 1,362 | +1,362 | New | 2025-09-30 |
| Stonex Group Inc. | $2.00 | 0.04% | 758 | +758 | New | 2025-09-30 |
| Sassicaia Capital Advisers Llc | $2.00 | 0.03% | 639 | +639 | New | 2025-09-30 |
| Miracle Mile Advisors, Llc | $1.00 | 0.02% | 400 | +400 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $0 | 0.01% | 96 | -2 | -2.04% | 2025-09-30 |